Patents by Inventor Michael Rosenblatt

Michael Rosenblatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic analogs of PTH and PTHrP
    Patent number: 5717062
    Abstract: Cyclic analogs of PTH and PTHrP wherein a disulfide or amide bond links the side chains of residues A.sub.13 and A.sub.17, A.sub.26 and A.sub.30, or A.sub.13 and A.sub.17 and A.sub.26 and A.sub.30.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: Beth Israel Hospital Association
    Inventors: Michael Chorev, Michael Rosenblatt
  • Humoral hypercalcemic factor antagonists
    Patent number: 5114843
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide analogues is exemplified by an internal region of the N-terminus of humoral hypercalcemic factor hHCF, and truncations thereof: hHCF(14-34)NH.sub.2, hHCF(13-34)NH.sub.2, hHCF(12-34)NH.sub.2, hHCF(11-23)NH.sub.2, hHCF(10-34)NH.sub.2, hHCF(9-34)NH.sub.2, hHCF(8-34)NH.sub.2 and various amino acid substitutions.
    Type: Grant
    Filed: February 25, 1991
    Date of Patent: May 19, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Roberta L. McKee, Michael P. Caulfield, Ruth F. Nutt
  • Antagonists with position 13 modification
    Patent number: 5093233
    Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone (PTH), wherein Lys.sup.13 is substituted to increase the biological activity of the PTH analogues. Thus, there are disclosed peptides having the formulae:PTH(7-34)NH.sub.2 ;[Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; and,desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(8-34)NH.sub.2wherein Lys.sup.13 is modified in the epsilon-amino acid group by N,N-diisobutyl or 3-phenylpropanoyl.
    Type: Grant
    Filed: April 25, 1990
    Date of Patent: March 3, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt
  • Humoral hypercalcemic factor antagonists modified at position 13 by biotin
    Patent number: 5087561
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Michael Chorev, Eliahu Roubini, Ruth F. Nutt, Le T. Duong
  • Humoral hypercalcemic factor antagonists with modification at position 13 . . .
    Patent number: 5087562
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 is modified so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: April 25, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt
  • Parathyroid hormone antagonists with enhanced metabolic properties
    Patent number: 5001223
    Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein Phe.sup.7 is substituted by NMePhe, D-Phe, desamino Phe, or Met.sup.8 is substituted by NMeMet.
    Type: Grant
    Filed: March 2, 1989
    Date of Patent: March 19, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Lynn H. Caporale, Michael Chorev
  • Parathyroid hormone antagonists
    Patent number: 4968669
    Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein Gly.sup.12 is substituted by D-Trp, L-Trp, L- or D- alpha- or beta-naphthylalanine, or D- or L- alpha-MeTrp.
    Type: Grant
    Filed: April 21, 1989
    Date of Patent: November 6, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Michael Chorev
  • Parathyroid hormone antagonists with simplified synthetic methodology
    Patent number: 4771124
    Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone and methods of synthesis of such analogues. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein Trp.sup.23 is substituted by L-Phe or other hydrophobic amino acids such as Leu, Nle, Val, Tyr, beta-napthylalanine and alpha-napthylalanine.
    Type: Grant
    Filed: May 26, 1987
    Date of Patent: September 13, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Lynn H. Caporale, Ruth F. Nutt, Jay J. Levy, Michael Chorev
  • Inhibitors of peptide hormone action
    Patent number: 4423037
    Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein the three N-terminal amino acids are removed and zero or more of the next four N-terminal amino acids are removed sequentially from the N-terminus.
    Type: Grant
    Filed: May 13, 1982
    Date of Patent: December 27, 1983
    Assignee: The General Hospital Corporation
    Inventors: Michael Rosenblatt, John T. Potts, Jr.